Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Emcure Pharmaceuticals to Launch The 750 Mg Injectable Variant of Ferric Carboxymaltose
Details : Orofer (ferric carboxymaltose) which is capable of releasing iron, helping in the synthesis of haemoglobin and increases red blood cell count. As a result, it treats iron deficiency anaemia.
Product Name : Orofer
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
May 17, 2023
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Zentiva
Deal Size : Undisclosed
Deal Type : Acquisition
Zentiva Completes Major Product Acquisition from Tillomed Spain
Details : Through this acquisition, Zentiva will significantly increase its position in the Hospital sector and more specifically in the Oncology area with some value-added 16 products complementing the products recently launched.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 16, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Zentiva
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Iron Sucrose
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Emcure Pharma Launches Generic Drug for Hyperphosphatemia in Chronic Kidney Disease Patients
Details : The company launched generic version of sucroferric oxyhydroxide tablets, indicated for the control of increased serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
Product Name : Dynulta
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2020
Lead Product(s) : Iron Sucrose
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable